Facing a cancer diagnosis is no longer the death sentence it once was thanks to advances in science. But now a new hurdle that has nothing to do with the boundaries of modern medicine threatens the ability of patients to receive timely treatment with vital chemotherapy.
During 2023, U.S. healthcare providers across the country have lacked sufficient supplies of over 300 different active drugs, the worst shortage in nearly a decade. Supplies of critical generic cancer drugs have plunged by almost 50% because of "economic reasons," according to the White House.
